| 2.25 0.07 (3.21%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.88 | 1-year : | 3.36 |
| Resists | First : | 2.47 | Second : | 2.88 |
| Pivot price | 1.76  |
|||
| Supports | First : | 1.8 | Second : | 1.38 |
| MAs | MA(5) : | 2.17 |
MA(20) : | 1.68 |
| MA(100) : | 1.7  |
MA(250) : | 2.37 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 80 |
| RSI | RSI(14): 71.8 |
|||
| 52-week | High : | 5.48 | Low : | 1.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MGX ] has closed below upper band by 10.9%. Bollinger Bands are 143% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.34 - 2.35 | 2.35 - 2.36 |
| Low: | 2.08 - 2.1 | 2.1 - 2.11 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Tue, 10 Jun 2025
Metagenomi CEO Thomas Brian sells shares worth $18,873 By Investing.com - Investing.com India
Tue, 13 May 2025
Metagenomi Q1 Earnings: Breakthrough Hemophilia Treatment Maintains 75% Effectiveness After 19 Months - Stock Titan
Mon, 17 Mar 2025
Metagenomi Reports Business Updates and Full Year 2024 Financial Results - GlobeNewswire
Wed, 22 Jan 2025
People are buying the wrong stock thinking it's part of OpenAI's Stargate Project - Quartz
Tue, 13 Feb 2024
Metagenomi Announces Closing of Initial Public Offering - Stock Titan
Wed, 10 Jan 2024
Metagenomi Begins Genetic Treatment IPO Rollout (Pending:MGX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 28.2 (%) |
| Held by Institutions | 26.4 (%) |
| Shares Short | 2,100 (K) |
| Shares Short P.Month | 2,400 (K) |
| EPS | -1.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | -172.3 % |
| Operating Margin | -674.1 % |
| Return on Assets (ttm) | -15.4 % |
| Return on Equity (ttm) | -32 % |
| Qtrly Rev. Growth | -63 % |
| Gross Profit (p.s.) | -1.55 |
| Sales Per Share | 1.21 |
| EBITDA (p.s.) | -2.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -102 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -1.22 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 1.85 |
| Price to Cash Flow | -0.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|